Archive | Melanoma In The News

Disease-Free Survival Gains Reported for Vemurafenib in Stage IIC-IIIB Melanoma

Adjuvant therapy with vemurafenib (Zelboraf) for high-risk melanoma led to mixed results, as patients with stage IIIC did not benefit, but those with earlier stage disease did, according to data reported at the 2017 ESMO Congress in Madrid.

Read the full story

Posted in Melanoma In The News, Information

Neoadjuvant Dabrafenib/Trametinib Leads to High pCR Rates in Bulky Resectable Melanoma, But Recurrences Are Common

Phase II results demonstrated that nearly half of patients with resectable stage IIIB/C BRAF V600-mutant melanoma achieved pathologic complete response (pCR) with neoadjuvant combination therapy consisting of dabrafenib (Tafinlar) and trametinib (Mekinist).

Read the full story

Posted in Melanoma In The News, Information

FDA accepts application for binimetinib-encorafenib combination for BRAF-mutated melanoma

The FDA accepted for review new drug applications that seek the use of the COMBO450 regimen to treat patients with BRAF-mutant advanced, unresectable or metastatic melanoma, according to the drugs’ manufacturer.

Read the full story

Posted in Melanoma In The News, FDA

Herpes Virus-Immunotherapy Combo Improves Melanoma Treatment

Melanoma is known to be a very aggressive and deadly form of skin cancer. Treatment can be challenging due to the likelihood of metastasis and drug-resistance.

Read the full story

Posted in Melanoma In The News, Information

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories